Companies will provide classification information on EGFR mutations in non-small cell lung cancer that may guide clinical decision-making In a retrospective analysis, the MD Anderson EGFR ...
HOUSTON ― Researchers from The University of Texas MD Anderson Cancer Center have discovered that grouping epidermal growth factor receptor (EGFR) mutations by structure and function provides an ...
The University of Texas MD Anderson Cancer Center today announced licensing agreements with BostonGene Corporation and Tempus for the MD Anderson EGFR Classification, which groups EGFR mutations in ...
Robert Brooks will outline the clinical progress, commercial potential and global development strategy for Radiance’s lead asset, RB-601 — the first in class bispecific nano ADC engineered to ...
Safety and tolerability of the olaparib tablet formulation in Japanese patients (pts) with advanced solid tumors (ASTs). This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This ...
BOSTON--(BUSINESS WIRE)--Scorpion Therapeutics, Inc. (“Scorpion Therapeutics”), a pioneering biotechnology company redefining the frontier of precision medicine through its Precision Oncology 2.0 ...
CNS activity observed at multiple dose levels, including the first reported confirmed CNS complete response by an EGFR exon 20 inhibitor in a patient with documented untreated brain metastases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results